Lizolid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lizolid

What is Lizolid? Identity and Classification

Property Description
Active ingredient Linezolid
Form Tablet, oral suspension, solution for infusion
Pharmacological class Oxazolidinone Antibiotic
General purpose Combatting systemic bacterial infections
Origin Synthetic

What is Lizolid and What Class of Antibiotic is Linezolid?

Lizolid is a prescription-only pharmaceutical preparation whose active compound is Linezolid, classified as a highly specialized synthetic antibacterial agent. It is the first commercially available member of the oxazolidinone class of antibiotics, which establishes its unique pharmacological position. The active ingredient Linezolid is clinically recognized for its utility against pathogens resistant to other drug types. Linezolid is entirely synthetic, possessing a unique acetamide-oxazolidinone structure that allows it to operate differently within the bacterial cell, thus establishing its importance in managing serious infections.

Composition and Available Forms of Linezolid

Linezolid is formulated as a single-ingredient product, containing only the active pharmaceutical ingredient, Linezolid, along with necessary excipients. The medicine is manufactured in three primary dosage form(s) to ensure flexibility in treatment: the film-coated tablet and oral suspension for administration via the oral route, and a solution for infusion for the intravenous (IV) route. This availability of both oral and intravenous preparations is a key feature, offering comparable bioavailability, allowing for convenient transition from hospital-based to outpatient care.

What is the General Purpose of the Oxazolidinone Class?

The general purpose of the oxazolidinone class is to provide a systemic anti-infective agent to manage serious bacterial illnesses, particularly those caused by pathogens resistant to common antibiotics. Linezolid achieves this by executing a bacteriostatic action by inhibiting a critical step in bacterial protein synthesis. This action indicates the medicine works by stopping bacteria from multiplying. By binding to the 50S ribosomal subunit, Linezolid effectively stops the bacteria from manufacturing the proteins they need to multiply, thereby helping the body control the infection caused by susceptible organisms.

What side effects are possible with Lizolid?

Possible Side Effects and Safety Information for Lizolid

Lizolid (linezolid) is associated with a distinct safety profile defined by serious adverse reactions and drug interactions, as documented in regulatory sources.

Common Adverse Reactions (most frequently reported in clinical trials, typically >5% of adult and/or pediatric patients) often involve the gastrointestinal and nervous systems. These include diarrhea, nausea, vomiting, and headache. Anemia is also commonly reported.


Serious and Clinically Significant Adverse Reactions

Serious concerns highlighted in official documents include several systemic risks, with the likelihood of occurrence often linked to the duration of treatment, particularly when exceeding the recommended 28 days.

  • Myelosuppression: This involves the bone marrow's reduced production of blood cells, potentially leading to thrombocytopenia (low platelets), anemia, leukopenia, and pancytopenia. The risk is increased with longer use, and weekly monitoring of complete blood counts (CBCs) is mandated.
  • Neuropathies: Both peripheral neuropathy and optic neuropathy (sometimes leading to vision loss) have been reported, primarily with extended use (over 28 days).
  • Serotonin Syndrome: Due to Lizolid's reversible, non-selective Monoamine Oxidase Inhibitor (MAOI) activity, there is a risk of Serotonin Syndrome when co-administered with other serotonergic agents (e.g., certain antidepressants). This is a potentially life-threatening condition.
  • Lactic Acidosis: This has been reported, often presenting with recurrent nausea/vomiting, abdominal pain, or fast breathing.
  • Clostridium difficile-associated Diarrhea (CDAD) / Colitis: Like many antibiotics, Lizolid can alter the gut flora, leading to CDAD.

Safety Considerations and Restrictions

Contraindications include known hypersensitivity to the drug and concomitant use with any medicinal product that inhibits MAO-A or MAO-B, or within two weeks of taking such a product. Caution is advised in patients with uncontrolled hypertension, pheochromocytoma, or thyrotoxicosis. Patients with severe renal or moderate to severe hepatic impairment may experience thrombocytopenia more frequently. The oral suspension contains phenylalanine and requires caution in patients with Phenylketonuria (PKU). A mortality imbalance was observed in an investigational study when the drug was used for catheter-related bloodstream infections, limiting its scope of approval.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information confirms that no specific antidote is known for Lizolid (Linezolid) overdose. The mandated treatment approach involves general symptomatic and supportive measures. The label notes that hemodialysis may be used if clinically necessary, a procedure that removes approximately 30% of the drug, though it is more effective at clearing the primary metabolites.

Regulators document that an overdose may present with clinical manifestations such as seizures and tremors, as well as vomiting. Non-human data cited in the overdosage section also report signs like ataxia (involuntary lack of coordination) and decreased activity.

Overdose is associated with the risk of severe, life-threatening outcomes, including Lactic Acidosis and Serotonin Syndrome. Official guidance mandates that immediate medical attention must be sought if an overdose is suspected. Regulators instruct the public to call emergency services immediately if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Lizolid

Main Uses of Lizolid

Lizolid, which contains the active ingredient linezolid, is an oxazolidinone antibiotic used to treat serious bacterial infections. It is specifically designed to target Gram-positive bacteria, including strains that have developed resistance to other types of antibiotics.

Bacterial Pneumonia

Lizolid is utilized in the treatment of pneumonia acquired in both community and hospital settings. It is effective against infections caused by Streptococcus pneumoniae and Staphylococcus aureus (including methicillin-resistant strains, often referred to as MRSA). By inhibiting the bacteria's ability to produce essential proteins, the medication helps the body’s immune system clear the infection from the lungs.

Skin and Soft Tissue Infections

The medication is indicated for various skin infections, ranging from uncomplicated to complex cases. These may include:

  • Cellulitis: Infection of the deeper layers of the skin.
  • Abscesses: Localized collections of pus within the tissue.
  • Diabetic foot infections: Serious complications involving the skin and underlying soft tissues of the feet in diabetic patients.

Vancomycin-Resistant Enterococcus (VRE) Infections

One of the primary benefits of Lizolid is its effectiveness against Enterococcus faecium infections that are resistant to vancomycin. VRE infections are often difficult to treat and can occur in the bloodstream, urinary tract, or at surgical wound sites. Lizolid provides a therapeutic option when traditional antibiotics are no longer effective.

Key Benefits

Activity Against Resistant Strains

A significant benefit of Lizolid is its activity against multi-drug resistant organisms. Because it belongs to a unique class of antibiotics, it works differently than penicillins, cephalosporins, or vancomycin, allowing it to bypass many common bacterial resistance mechanisms.

High Bioavailability

Lizolid is characterized by high bioavailability, meaning the medication is efficiently absorbed by the body. This allows for a consistent therapeutic effect whether administered in a clinical setting or continued during recovery at home.

Targeted Action

The drug acts by binding to the bacterial ribosome, preventing the initiation of protein synthesis. This targeted mechanism is bacteriostatic against enterococci and staphylococci, meaning it stops their growth, and bactericidal against most strains of streptococci, meaning it kills the bacteria directly.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Lizolid (Linezolid) eligibility is determined by formal criteria established in regulatory documents concerning patient characteristics and pre-existing conditions.

Absolute Non-Eligibility

Use of this medicine is contraindicated in patients with a known hypersensitivity to linezolid or any product component. The medicine must also not be used in patients who are currently taking or have recently taken (within the last two weeks) any Monoamine Oxidase Inhibitor (MAOI).

Restricted or Conditional Use

Special caution and close monitoring are required for use in patients with severe renal impairment (including those on haemodialysis) or moderate to severe hepatic impairment. Use is generally reserved for cases where the anticipated benefit justifies the theoretical risk. Patients with pre-existing myelosuppression must be closely monitored throughout treatment. Furthermore, the medicine is not recommended for children weighing less than 5 kg, and breastfeeding must be discontinued during therapy. Individuals with uncontrolled hypertension or certain psychiatric conditions are restricted from use unless continuous blood pressure monitoring is feasible.

What should I know about interactions with other medicines?

Lizolid Interactions with Other Medicines and Products

Lizolid (Linezolid) possesses a unique interaction profile due to its function as a reversible, non-selective Monoamine Oxidase Inhibitor (MAOI). This property dictates key restrictions and prohibitions documented in official regulatory labeling.

Formally Contraindicated Combinations

Classification Examples of Interacting Medicines Interaction Basis
Absolute Contraindication Other non-selective MAOIs (e.g., phenelzine, tranylcypromine) MAOI activity of Linezolid
Conditional Contraindication Serotonergic psychiatric medicines (SSRIs, SNRIs) Risk of Serotonin Syndrome
Conditional Contraindication Adrenergic and Vasopressive Agents (e.g., pseudoephedrine, dopamine) Risk of Hypertensive Crisis

Other Documented Interactions and Constraints

The label notes that the enzyme inducer Rifampicin can reduce Linezolid exposure (AUC) by approximately 30%. Regarding dietary intake, the consumption of high amounts of tyramine-rich foods and beverages (such as aged cheese or red wine) is officially restricted due to the potential for a hypertensive reaction.

Officially documented timing rules mandate that other MAOIs must be discontinued for at least two weeks before initiating Lizolid therapy. For specific populations, the accumulation of Linezolid's metabolites is noted as a caution in patients with severe renal impairment.

Mechanism of Action

️ Targeting Bacterial Protein Synthesis Initiation

Linezolid, the active compound in Lizolid, exerts its primary action by engaging a distinct molecular target: the 23S ribosomal RNA (rRNA) component of the bacteria’s 50S ribosomal subunit. By binding to this site, Linezolid functions as an inhibitory blockade, preventing the formation of the 70S initiation complex, which is the initial step in protein synthesis. This unique mechanism arrests the production of all proteins essential for cell growth and replication, resulting in the bacteriostatic effect due to the arrest of cell replication.


Limitations from Efflux and Target Modification

The functionality of this ribosomal mechanism is constrained by certain physiological factors in some bacteria. Some bacteria employ efflux pumps to actively expel the drug before it can reach its ribosomal target. Furthermore, the binding site can be physically altered by mutations in the 23S rRNA or the presence of the Cfr gene, which reduces Linezolid's binding affinity. These limitations represent mechanisms that reduce the drug's inhibitory power, resulting in continued protein synthesis and growth within the resistant organism.


Modulation of Human Monoamine Homeostasis

In addition to its antibacterial role, Linezolid possesses a secondary pharmacological activity as a reversible, non-selective inhibitor of human Monoamine Oxidase (MAO) enzymes. By blocking the MAO enzymes, the drug prevents the enzymatic breakdown of key neurotransmitters, including serotonin and norepinephrine. This modulation causes an elevated concentration of these monoamines within the nervous system.

Dosage and Administration Information

How to Use Lizolid

Lizolid (Linezolid) administration is governed by specific guidelines that define the permitted routes, standard dosages, and duration of use, ensuring consistency across treatment settings.

Administration Routes and Flexibility

Lizolid is approved for administration via the oral route (film-coated tablets or suspension) and the intravenous (IV) route (solution for infusion). A key principle of usage is that the oral and intravenous doses are functionally equivalent, allowing patients to transition between IV therapy, typically started in a hospital setting, and oral therapy without requiring dose adjustment.

Dosing and Treatment Duration

Parameter Standard Usage Guideline
Standard Adult Dose 600 mg
Frequency Every 12 hours (twice daily)
Pneumonia/SSSI Duration 10 to 14 consecutive days
VRE Infection Duration 14 to 28 consecutive days
Maximum Duration 28 days

The standard adult dose is 600 mg, administered every 12 hours for all major approved indications. Pediatric dosing (birth to 11 years) is weight-based at 10 mg/kg per dose and is typically given every 8 hours.

Contextual and Procedural Requirements

Lizolid can be taken without regard to meals. The IV infusion must be administered slowly, taking between 30 and 120 minutes. No dose adjustment is generally required for older adults or patients with renal or hepatic impairment, simplifying the regimen across these populations. Patients undergoing hemodialysis should receive their dose after the dialysis session is complete.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lizolid (Linezolid)

Evidence for Use in VRE Infections

Research exploring Lizolid's role in managing Vancomycin-Resistant Enterococcus faecium (VRE) infections has included randomized controlled trials (RCTs) and observational studies. This evidence base was built largely using studies that included hospitalized adults with confirmed VRE, often focusing on those with serious complications like bacteremia (bacteria in the bloodstream).

The primary focus of these studies was to measure outcomes related to the infection, such as whether patients achieved clinical cure and microbiological eradication. Findings describe patterns observed in the studies related to the frequency of achieving clinical resolution and microbiological clearance. Scientific reviews suggest the need for more extensive, large-scale studies specifically for VRE bacteremia, and long-term outcomes are not consistently well-characterized.


Evidence for Use in Complicated Skin and Skin Structure Infections (cSSSIs)

The evidence for Lizolid's use in complicated skin and skin structure infections (cSSSIs) is based on large, well-designed randomized controlled trials (RCTs). These trials often used a non-inferiority design, meaning they were designed to evaluate outcomes against a comparator treatment commonly used at the time. The research examined conditions such as deep tissue infections, including specific cases like diabetic foot infections that do not involve underlying bone infection.

The main outcomes that studies monitored were the frequency of Clinical Success/Cure and Microbiological Success. The large comparative RCTs reported the percentage of patients who achieved clinical success, with study reports describing findings consistent with the trial’s non-inferiority criteria relative to the comparator. Analyses sometimes show heterogeneity when comparing results from different trial designs, and data for certain outpatient subgroups are less commonly represented in the pivotal trials.


Evidence for Use in Bacterial Pneumonia

Lizolid was studied for use in bacterial pneumonia, including infections acquired in the hospital (Hospital-Acquired Pneumonia, HAP) and some Community-Acquired Pneumonia (CAP), with a focus on those caused by specific bacteria like MRSA. The research included randomized controlled trials (RCTs) that compared Lizolid to standard treatments, designed to explore treatment differences against a comparator.

Studies monitored patient response, measuring the rate of Clinical Cure and the frequency of Microbiological Eradication, and metrics of Mortality/Survival in the studied hospitalized patients. Data analyses described the patterns observed in all-cause mortality measurements across different treatment arms and pneumonia types. Regulatory reviews noted the need for careful interpretation of mortality data due to potential differences in severity among the patient groups in certain original trials.

Frequently Asked Questions (FAQ)

Common questions about Lizolid (FAQ)


Q: How is Lizolid different from penicillin or other common antibiotics?

A: Lizolid belongs to a unique chemical group called Oxazolidinone antibiotics, which is distinct from groups like penicillin. Official information explains that Linezolid works by blocking the initial step of bacterial protein synthesis, a mechanism that is different from how many common antibiotics function to stop bacteria.


Q: Can I take regular pain relievers like ibuprofen with Lizolid?

A: Regulatory guidance advises caution when Lizolid is used with medications that can raise blood pressure, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen. Due to the potential for affecting blood pressure, official information notes that close monitoring may be involved when this combination is used.


Q: How long after stopping Lizolid can side effects still occur?

A: Official warnings indicate that certain serious side effects, such as damage to the nerves (peripheral neuropathy) or vision loss (optic neuropathy), are mainly reported with extended use (over 28 days). These conditions have been reported to sometimes be irreversible, meaning the effects may persist after the drug is stopped.


Q: What is the safety classification of Lizolid for use during pregnancy?

A: In the United States, Lizolid is summarized in regulatory documents as a Pregnancy Category C medicine. This category signifies that animal studies showed some risk to the fetus, but there is no adequate data from human studies. Regulatory labeling indicates that the use of the medicine during pregnancy is generally reserved for situations where the potential benefit is considered to outweigh the potential risk.


Q: Is Lizolid found in breast milk if a mother is taking it?

A: It is not known whether the active ingredient, Linezolid, passes into human breast milk. However, due to the regulatory caution that many medicines can be found in human milk, official warnings recommend that a mother discontinue breastfeeding while receiving treatment with Lizolid.


Q: What is the purpose of the routine blood work while on Lizolid?

A: The purpose of the required routine blood work, specifically Complete Blood Counts (CBCs), is to check for a condition called Myelosuppression. This is a serious side effect where the bone marrow reduces its production of blood cells, and the risk increases with longer use of the medicine.


Q: Do studies support the use of Lizolid for multi-drug resistant tuberculosis?

A: While Lizolid is not officially approved by major regulatory bodies for treating tuberculosis (TB), its use in managing multidrug-resistant TB (MDR-TB) is recognized and discussed in global public health guidelines. This recognition is often based on the drug’s observed utility in managing pathogens that show resistance to standard treatments.


Q: Do people typically take Lizolid for common colds or flu?

A: Official information explicitly notes that Lizolid is an antibiotic that is active only against bacterial infections. Because common colds and the flu are caused by viruses, Lizolid will not work to treat them.


Q: Is it common to feel tired or weak while on Lizolid?

A: General tiredness or weakness is not listed among the most commonly reported adverse reactions (such as diarrhea or headache). However, regulatory labels state that unusual tiredness or weakness may be a symptom of a rare but serious reaction called rhabdomyolysis, a condition involving muscle breakdown.


Q: Does Lizolid affect blood pressure?

A: Lizolid has secondary pharmacological activity as a Monoamine Oxidase Inhibitor (MAOI). Because of this, official warnings note that Lizolid can cause an increase in blood pressure when combined with certain foods or interacting medicines. Reports also note that blood pressure elevation has been rarely observed in some patients treated with Lizolid alone.


Q: Can Lizolid cause a metallic taste in the mouth?

A: Although it is not classified as one of the most common side effects, reports from regulatory adverse event systems sometimes include metallic or abnormal taste (known medically as dysgeusia) as a possible adverse reaction to Lizolid.


Q: Why does Lizolid sometimes interact with over-the-counter cold medicines?

A: This interaction occurs because Lizolid is an MAOI and many common cold remedies contain sympathomimetic or adrenergic agents (such as pseudoephedrine) that increase blood pressure. Combining these two types of agents carries an official warning due to the risk of a hypertensive crisis (a severe spike in blood pressure).


Q: Can alcohol be consumed safely while on Lizolid?

A: Official information recommends avoiding the use of alcohol while taking Lizolid. This is because alcohol may increase certain nervous system side effects of the medicine, such as dizziness, drowsiness, and difficulty concentrating.


Q: How long does Lizolid stay in the body after the last dose?

A: According to official pharmacokinetic data, the average half-life of Linezolid in the body is approximately 4.5 to 5.5 hours. This refers to the time it takes for half of the drug to be cleared. The medicine is primarily cleared from the body through metabolism and excretion by the kidneys.


Q: Why is Lizolid sometimes referred to as an Oxazolidinone?

A: Lizolid is referred to as an Oxazolidinone because its active compound, Linezolid, is the first commercially available drug in the Oxazolidinone chemical class of antibiotics. This classification is based on the drug's unique chemical structure.


Q: Is Lizolid ever used to prevent infections?

A: The official indications for Lizolid are focused on the treatment of specified, established bacterial infections, such as certain pneumonias and skin infections. Regulatory documents do not include use for prophylaxis (preventing infection) within its scope of approval.


Q: What does official guidance say about driving while taking Lizolid?

A: Official guidance warns that Lizolid may cause dizziness or vision problems. Official guidance includes a warning that patients should use caution regarding activities like driving or operating machinery until they have determined how the medicine affects their ability to perform these tasks.


Q: Is it true that Lizolid can impact the production of blood cells?

A: Yes, official warnings confirm a risk of Myelosuppression. This is a serious condition that involves the bone marrow's reduced production of blood cells, which can result in low counts of red cells (anemia) and platelets (thrombocytopenia).


Q: Can Lizolid be used in people who are allergic to sulfa drugs?

A: Regulatory information confirms that the active ingredient, Linezolid, is chemically distinct and is not a sulfonamide. Because of its different structure, it is generally considered an alternative option for patients who have a confirmed allergy to sulfonamide-containing antibiotics.


Q: Is it normal to feel dizzy when first starting Lizolid?

A: The regulatory label lists dizziness as a reported side effect of Lizolid, although it is not classified among the most frequently reported adverse reactions. Dizziness is also cited as a reason to exercise caution when engaging in activities like driving.


Q: Is the liquid form of Lizolid as effective as the tablet form?

A: Official regulatory documents state that the liquid oral suspension and the film-coated tablets are formulated to deliver the same amount of active ingredient. Both forms are considered pharmacologically equivalent (bioequivalent) for oral administration, meaning they deliver the active ingredient in a comparable way.

How should Lizolid be stored and disposed of?

How to Store and Dispose of Lizolid?

Lizolid (linezolid) formulations should be stored properly to maintain effectiveness. The oral tablets and oral suspension should generally be kept at room temperature, away from excess heat, moisture, and direct light. The oral suspension must be used within 21 days after it is prepared. IV infusion bags should be stored in their foil overwrap until ready for use and protected from freezing.

Formulation General Storage Conditions
Oral Tablets Room temperature, protected from moisture and light
Oral Suspension Room temperature; discard any unused portion after 21 days
IV Injection Room temperature; protect from freezing; keep in overwrap until use

All medications should be kept securely out of the sight and reach of children. Do not dispose of unused or expired Lizolid down the toilet or drain unless specifically instructed to do so by local guidelines or a healthcare professional. Unneeded medication should be disposed of properly via a drug take-back program or following instructions from a pharmacist to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lizolid found in:

A-Z Index: